Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
1728 | 2515 | 43.8 | 82% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
11 | 4 | NEUROSCIENCES//CLINICAL NEUROLOGY//NEUROL | 1112395 |
497 | 3 | CANNABINOID//ANANDAMIDE//ENDOCANNABINOIDS | 22707 |
1435 | 2 | TRPV1//TRPA1//CAPSAICIN | 7869 |
1728 | 1 | TRPV1//CAPSAICIN//RESINIFERATOXIN | 2515 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | TRPV1 | authKW | 1856440 | 16% | 39% | 395 |
2 | CAPSAICIN | authKW | 1342710 | 25% | 18% | 631 |
3 | RESINIFERATOXIN | authKW | 909779 | 5% | 56% | 133 |
4 | CAPSAZEPINE | authKW | 779341 | 4% | 61% | 106 |
5 | VANILLOID RECEPTOR | authKW | 634234 | 5% | 42% | 125 |
6 | TRPV1 ANTAGONIST | authKW | 547072 | 2% | 87% | 52 |
7 | VANILLOID | authKW | 543313 | 3% | 51% | 88 |
8 | VR1 | authKW | 449504 | 2% | 63% | 59 |
9 | VANILLOID RECEPTOR 1 | authKW | 368911 | 2% | 62% | 49 |
10 | CAPSAICIN RECEPTOR | authKW | 241924 | 1% | 59% | 34 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Neurosciences | 11212 | 39% | 0% | 992 |
2 | Pharmacology & Pharmacy | 4788 | 27% | 0% | 677 |
3 | Anesthesiology | 1936 | 6% | 0% | 140 |
4 | Chemistry, Medicinal | 1657 | 8% | 0% | 208 |
5 | Physiology | 1326 | 9% | 0% | 221 |
6 | Clinical Neurology | 227 | 6% | 0% | 144 |
7 | Biochemistry & Molecular Biology | 148 | 11% | 0% | 282 |
8 | Chemistry, Organic | 87 | 4% | 0% | 111 |
9 | Behavioral Sciences | 75 | 2% | 0% | 43 |
10 | Medicine, Research & Experimental | 71 | 3% | 0% | 81 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | SENSORY GRP | 64739 | 0% | 67% | 8 |
2 | LEADING MOL MODELING DRUG DESIGN | 61448 | 0% | 56% | 9 |
3 | NANOMED MOL INTERVENT | 54071 | 0% | 64% | 7 |
4 | GRUNENTHAL INNOVAT | 51743 | 0% | 47% | 9 |
5 | NEURONAL GENE EXP S UNIT | 49564 | 0% | 58% | 7 |
6 | CORE CELL SIGNALING DRUG DISCOVERY | 45693 | 0% | 47% | 8 |
7 | CELLULAR CARCINOGENESIS TUMOR PROMOT | 43793 | 1% | 11% | 34 |
8 | ENDOCANNABINOID GRP | 42087 | 2% | 8% | 41 |
9 | PRECLIN COMPOUND PROFILING | 36418 | 0% | 100% | 3 |
10 | MOL MECHANISMS TUMOR PROMOT SECT | 25285 | 0% | 42% | 5 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | MOLECULAR PAIN | 11843 | 1% | 3% | 29 |
2 | PAIN | 9582 | 3% | 1% | 79 |
3 | NEUROSCIENCE LETTERS | 5947 | 5% | 0% | 125 |
4 | NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 5341 | 2% | 1% | 52 |
5 | ACTA PHYSIOLOGICA HUNGARICA | 4757 | 1% | 2% | 22 |
6 | EUROPEAN JOURNAL OF PHARMACOLOGY | 4355 | 4% | 0% | 102 |
7 | NEUROSCIENCE | 3879 | 3% | 0% | 85 |
8 | BRITISH JOURNAL OF PHARMACOLOGY | 3442 | 3% | 0% | 72 |
9 | BRAIN RESEARCH | 2221 | 4% | 0% | 96 |
10 | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2121 | 3% | 0% | 68 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | TRPV1 | 1856440 | 16% | 39% | 395 | Search TRPV1 | Search TRPV1 |
2 | CAPSAICIN | 1342710 | 25% | 18% | 631 | Search CAPSAICIN | Search CAPSAICIN |
3 | RESINIFERATOXIN | 909779 | 5% | 56% | 133 | Search RESINIFERATOXIN | Search RESINIFERATOXIN |
4 | CAPSAZEPINE | 779341 | 4% | 61% | 106 | Search CAPSAZEPINE | Search CAPSAZEPINE |
5 | VANILLOID RECEPTOR | 634234 | 5% | 42% | 125 | Search VANILLOID+RECEPTOR | Search VANILLOID+RECEPTOR |
6 | TRPV1 ANTAGONIST | 547072 | 2% | 87% | 52 | Search TRPV1+ANTAGONIST | Search TRPV1+ANTAGONIST |
7 | VANILLOID | 543313 | 3% | 51% | 88 | Search VANILLOID | Search VANILLOID |
8 | VR1 | 449504 | 2% | 63% | 59 | Search VR1 | Search VR1 |
9 | VANILLOID RECEPTOR 1 | 368911 | 2% | 62% | 49 | Search VANILLOID+RECEPTOR+1 | Search VANILLOID+RECEPTOR+1 |
10 | CAPSAICIN RECEPTOR | 241924 | 1% | 59% | 34 | Search CAPSAICIN+RECEPTOR | Search CAPSAICIN+RECEPTOR |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | HOLZER, P , (1991) CAPSAICIN - CELLULAR TARGETS, MECHANISMS OF ACTION, AND SELECTIVITY FOR THIN SENSORY NEURONS.PHARMACOLOGICAL REVIEWS. VOL. 43. ISSUE 2. P. 143-201 | 227 | 49% | 1415 |
2 | HOLZER, P , (2008) THE PHARMACOLOGICAL CHALLENGE TO TAME THE TRANSIENT RECEPTOR POTENTIAL VANILLOID-1 (TRPV1) NOCISENSOR.BRITISH JOURNAL OF PHARMACOLOGY. VOL. 155. ISSUE 8. P. 1145 -1162 | 163 | 75% | 84 |
3 | SZALLASI, A , BLUMBERG, PM , (1999) VANILLOID (CAPSAICIN) RECEPTORS AND MECHANISMS.PHARMACOLOGICAL REVIEWS. VOL. 51. ISSUE 2. P. 159 -211 | 188 | 43% | 1216 |
4 | PREMKUMAR, LS , SIKAND, P , (2008) TRPV1: A TARGET FOR NEXT GENERATION ANALGESICS.CURRENT NEUROPHARMACOLOGY. VOL. 6. ISSUE 2. P. 151-163 | 138 | 72% | 34 |
5 | CUI, M , GOSU, V , BASITH, S , HONG, S , CHOI, S , (2016) POLYMODAL TRANSIENT RECEPTOR POTENTIAL VANILLOID TYPE 1 NOCISENSOR: STRUCTURE, MODULATORS, AND THERAPEUTIC APPLICATIONS.ION CHANNELS AS THERAPEUTIC TARGETS, PT B. VOL. 104. ISSUE . P. 81 -125 | 120 | 64% | 2 |
6 | VALENZANO, KJ , SUN, Q , (2004) CURRENT PERSPECTIVES ON THE THERAPEUTIC UTILITY OF VR1 ANTAGONISTS.CURRENT MEDICINAL CHEMISTRY. VOL. 11. ISSUE 24. P. 3185-3202 | 128 | 78% | 33 |
7 | BISHNOI, M , PREMKUMAR, LS , (2011) POSSIBLE CONSEQUENCES OF BLOCKING TRANSIENT RECEPTOR POTENTIAL VANILLOID 1.CURRENT PHARMACEUTICAL BIOTECHNOLOGY. VOL. 12. ISSUE 1. P. 102-114 | 142 | 59% | 3 |
8 | PREMKUMAR, LS , BISHNOI, M , (2011) DISEASE-RELATED CHANGES IN TRPV1 EXPRESSION AND ITS IMPLICATIONS FOR DRUG DEVELOPMENT.CURRENT TOPICS IN MEDICINAL CHEMISTRY. VOL. 11. ISSUE 17. P. 2192 -2209 | 154 | 52% | 12 |
9 | PALAZZO, E , LUONGO, L , DE NOVELLIS, V , ROSSI, F , MARABESE, I , MAIONE, S , (2012) TRANSIENT RECEPTOR POTENTIAL VANILLOID TYPE 1 AND PAIN DEVELOPMENT.CURRENT OPINION IN PHARMACOLOGY. VOL. 12. ISSUE 1. P. 9 -17 | 93 | 74% | 28 |
10 | SZALLASI, A , CORTRIGHT, DN , BLUM, CA , EID, SR , (2007) THE VANILLOID RECEPTOR TRPV1: 10 YEARS FROM CHANNEL CLONING TO ANTAGONIST PROOF-OF-CONCEPT.NATURE REVIEWS DRUG DISCOVERY. VOL. 6. ISSUE 5. P. 357 -372 | 93 | 55% | 404 |
Classes with closest relation at Level 1 |